Literature DB >> 15377460

Strategies in the treatment of acute myeloid leukemia.

Böb Lowenberg.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15377460

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  4 in total

1.  Genomic impact of transient low-dose decitabine treatment on primary AML cells.

Authors:  Jeffery M Klco; David H Spencer; Tamara L Lamprecht; Shawn M Sarkaria; Todd Wylie; Vincent Magrini; Jasreet Hundal; Jason Walker; Nobish Varghese; Petra Erdmann-Gilmore; Cheryl F Lichti; Matthew R Meyer; R Reid Townsend; Richard K Wilson; Elaine R Mardis; Timothy J Ley
Journal:  Blood       Date:  2013-01-07       Impact factor: 22.113

2.  Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML.

Authors:  Lyoung Hyo Kim; Hyun Sub Cheong; Youngil Koh; Kwang-Sung Ahn; Chansu Lee; Hyung-Lae Kim; Hyoung Doo Shin; Sung-Soo Yoon
Journal:  J Hum Genet       Date:  2015-09-10       Impact factor: 3.172

Review 3.  Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications.

Authors:  Maria Ilaria Del Principe; Francesco Buccisano; Luca Maurillo; Giuseppe Sconocchia; Mariagiovanna Cefalo; Maria Irno Consalvo; Chiara Sarlo; Consuelo Conti; Giovanna De Santis; Eleonora De Bellis; Ambra Di Veroli; Patrizia Palomba; Cristina Attrotto; Annagiulia Zizzari; Giovangiacinto Paterno; Maria Teresa Voso; Giovanni Del Poeta; Francesco Lo-Coco; William Arcese; Sergio Amadori; Adriano Venditti
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-10-20       Impact factor: 2.576

Review 4.  Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?

Authors:  Federico Mosna; Debora Capelli; Michele Gottardi
Journal:  J Clin Med       Date:  2017-06-03       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.